The Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision (CONNECT) Trial The Value of Remote Monitoring George H. Crossley, MD.

Slides:



Advertisements
Similar presentations
Agenda Introduction Classes of recommendations Level of evidence
Advertisements

Linoxsmart S DX Master Study
Prevalence and Predictors of Off-label Use of Cardiac Resynchronization Therapy: A Report from the ICD Registry TM Adam S. Fein * MD, Yongfei Wang ¥ MS,
The MADIT II Trial Multicenter Autonomic Defibrillator Implantation Trial II Presented at the American College of Cardiology 51st Annual Scientific Session.
Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010 ICD data.
Presenter Disclosure Information
Remote follow up: Where are we now? Has it improved services to our patients? LYDIA BRADLEY CRM DEVICES LEAD PHYSIOLOGIST.
EP Testing and Use of Devices in Heart Failure HFSA 2010 Recommendations.
Cardiac Insufficiency Bisoprolol Study (CIBIS III) Trial
Improving Evidence-Based Care for Heart Failure in Outpatient Cardiology Practices: Primary Results of the Registry to Improve Heart Failure Therapies.
Nurse Led Clinics Opportunity for nurses to make a difference Wilma Scholte op Reimer, RN, PhD Amsterdam School of Health Professions Academic Medical.
Primary Results from the SMART AV DELAY Trial: A Randomized Trial Comparing Empiric, Echocardiographic Guided and Algorithmic AV Delay Programming in Cardiac.
Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.
Improving Office Care for Chest Pain Thomas D. Sequist, MD MPH Associate Professor of Medicine and Health Care Policy Brigham and Women ’ s Hospital, Division.
Percutaneous Therapy of Pulmonic and Mitral Valve Disease Atman P. Shah MD FACC FSCAI Director, Coronary Care Unit Assistant Professor of Medicine The.
MADIT Randomized Trial to Reduce Inappropriate Therapy (MADIT-RIT) Arthur J. Moss, MD for the MADIT-RIT Executive Committee AHA Late Breaking Trials November.
The Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision (CONNECT) Trial The Value of Remote Monitoring George H. Crossley, MD.
Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure Presented at American College of Cardiology Scientific Sessions.
Implantable Cardioverter Defibrillators to Prevent Sudden Cardiac Death: Background Frederick A. Masoudi, MD, MSPH Associate Professor of Medicine (Cardiology)
Atrial Fibrillation and Sudden Death: Are they linked? Mariell Jessup MD Professor of Medicine University of Pennsylvania Philadelphia, Pennsylvania.
1 New Approaches to Monitoring Heart Failure Before Symptoms Appear William T. Abraham, MD, FACP, FACC Professor of Medicine Chief, Division of Cardiovascular.
Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,
SURGICAL ABLATION OF ATRIAL FIBRILLATION DURING MITRAL VALVE SURGERY THE CARDIOTHORACIC SURGICAL TRIALS NETWORK Marc Gillinov, M.D. For the CTSN Investigators.
Sex Differences in Implantable Cardioverter Defibrillator (ICD) Implantation indications and outcomes Guy Amit, MD; Mahmoud Suleiman, MD; Mark Kazatsker,
Prognostic Value of Programmed Electrical Stimulation Among Implantable Cardioverter-Defibrillator Recipients Real-World Data from the Israeli National.
Indications of ICD in 2010 Dr Mervat Aboulmaaty Professor of Cardiology Ain Shams University DAF 1 st EP course 2010.
Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.
Heart Failure Ben Starnes MD FACC Interventional Cardiology
The Latest Device Therapy in W. Herts Dr Philip Moore.
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
May 2005 EP Show The EP Show COMPANION and CARE-HF Eric Prystowsky MD Director, Clinical Electrophysiology Laboratory St Vincent Hospital Indianapolis,
Presenter Disclosure Information John F. Beshai, MD RethinQ Trial Results Disclosures Information: The following relationships exist related to this presentation:
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Efficacy and safety of ivabradine in patients with severe chronic systolic.
The Studies of Oral Enoximone Therapy in Advanced Heart Failure ESSENTIALESSENTIAL Presented at The European Society of Cardiology Congress 2005 Presented.
CONFIDENTIAL SLIDE SET FOR THE CHAIR OF THE ACC08 Late Breaker; embargoed until 1 April 2008 Long-term Cardiac Arrhythmias recorded by Insertable Loop.
Grace Thacker Xavier University of Louisiana LSUHC – Internal Medicine
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
Atorvastatin for Reduction of Myocardial Dysrhythmias After Cardiac Surgery Trial Presented at The American College of Cardiology Scientific Sessions March.
INTRODUCTION: INTRODUCTION: implantable cardioverter-defibrillators (ICDs) have clearly demonstrated to terminate an elevated percentage of sustained ventricular.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Eric J Robinson, M.D. Cardiologist April 25, 2015
Increased Patient Device Concerns But Not General Anxiety in Patients with a Secondary Indication for the ICD Susanne S. Pedersen, Professor of Cardiac.
CoRPS Center of Research on Psychology in Somatic diseases Poor health status in implantable cardioverter defibrillator patients: Shock, patient pre implantation.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Risk Assessment and Comparative Effectiveness of.
CoRPS Disclosures None. CoRPS Center of Research on Psychology in Somatic diseases Impact of psychological profile in heart failure patients Susanne S.
Alireza Heidari Bakavoli, MD. Cardiology department Qaem medical center Mashhad University of Medical Science Role of ICD and CRT devices in Heart failure.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: Clinical Effectiveness of CRT and ICD Therapy in.
Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Influence of Left Ventricular Ejection Fraction.
CoRPS Center of Research on Psychology in Somatic diseases Depression is associated with a 2-fold independent risk of mortality in implantable cardioverter.
Author Disclosure Sex Differences in the Characteristics of Patients Receiving ICD Therapy for the Primary Prevention of Sudden Cardiac Death –Stacie L.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Remote Monitoring of Implantable Cardioverter-Defibrillators:
Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V.
Post-FDA Approval, Initial US Clinical Experience with Watchman Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation Vivek Y. Reddy.
BLOCK HF Study Biventricular versus Right Ventricular Pacing in Patients with Left Ventricular Dysfunction and Atrioventricular Block – Preliminary Results.
Update on the Watchman Device CRT 2010 Washington, DC
American College of Cardiology Presented by Dr. Stuart J. Connolly
TAVI Passed the Exam and is Ready for Clinical Use in Inoperable Patients Disclosures Research Funding and Speaking Honoraria: Edwards Lifesciences.
Felix Mahfoud Saarland University Hospital, Homburg, Germany
Update on PARADIGM-HF Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial John J.V.
Results from the PROVIDE Trial
O’Connor Efficacy and Safety of Exercise Training as a Treatment Modality in Patients With Chronic Heart Failure: Results of A Randomized Controlled.
EMPHASIS-HF Extended Follow-up
Optimal Pacing for Right Ventricular and Biventricular Devices
OptiLink HF Trial design: Patients with heart failure who underwent implantation of an ICD were randomized to telemonitoring (n = 505) vs. usual care (n.
Catheter Ablation for the Cure of Atrial Fibrillation Study
Volume 9, Issue 1, Pages (January 2012)
Univ. of Copenhagen, Denmark
Physical Counterpressure Maneuver (PC) Trial
The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter
Chest Pain Choice Trial design: Patients presenting to the ED with low risk chest pain were randomized to either use of a tailored decision aid or routine.
Presentation transcript:

The Clinical Evaluation of Remote Notification to Reduce Time to Clinical Decision (CONNECT) Trial The Value of Remote Monitoring George H. Crossley, MD President, Mid-State Cardiology, a unit of St. Thomas Heart Clinical Professor of Medicine, University of Tennessee College of Medicine ACC Governor, Tennessee

Disclosures CONSULTING FEES/HONORARIA Medtronic Inc Boeringer SPEAKER'S BUREAU Medtronic Sanofi RESEARCH/RESEARCH GRANTS Medtronic St Jude Sanofi

Study Purpose To demonstrate that remote monitoring with automatic clinician notifications reduces the time from a clinical event to a clinical decision in response to arrhythmias, cardiovascular disease progression, and device issues as compared to standard in-office care. Rates of cardiovascular health care utilization (HCU) between treatment groups

Study Design Randomized, multi-center prospective study –N = 1,997 newly implanted CRT-D and DR-ICD patients –136 US centers –Remote management system vs. standard In-office care –Patients followed remotely for 12 months (Remote Arm) Remote Arm 1014 pts Enrollment In-office Arm 983 pts 1 Month Office F/U Patient signs Informed Consent/HIPAA Authorization implanted with a study device and randomized Enrollment 1 Month Office F/U 3 Month Remote F/U3 Month Office F/U 6 Month Remote F/U6 Month Office F/U 9 Month Remote F/U9 Month Office F/U 12 Month Remote F/U12 Month Office F/U 15 Month Office F/U Crossley G, Boyle A, Vitense H, Sherfesee L, Mead RH. Trial design of the clinical evaluation of remote notification to reduce time to clinical decision: the Clinical evaluation Of remote NotificatioN to rEduCe Time to clinical decision (CONNECT) study. Am Heart J Nov;156(5): Epub 2008 Sep 11.

Required Study Programming RemoteIn-office Medtronic CareLink® Home MonitorProvidedNot Provided Clinical Management Alerts AT/AF BurdenAutomatic Clinician Alert, 12 hrs/dayOff Fast V. Rate during AT/AFAutomatic Clinician Alert, 120 bpm x 6 hrs AT/AF /dayOff Number of Shocks DeliveredAutomatic Clinician Alert, 2 Shocks DeliveredOff All Therapies Exhausted in a ZoneAutomatic Clinician AlertOff Lead / Device Integrity Alerts Lead Impedance Out of RangeAutomatic Clinician and Audible Patient AlertAudible Patient Alert VF Detection / Therapy OffAutomatic Clinician and Audible Patient AlertAudible Patient Alert Low Battery VoltageAutomatic Clinician and Audible Patient AlertAudible Patient Alert Excessive Charge TimeAutomatic Clinician and Audible Patient AlertAudible Patient Alert

Required Study Programming Midnight Day 1 Midnight Day 2 Midnight Day 3 Midnight Day 1 Midnight Day 2 Midnight Day 3 Atrial fibrillation

Required Study Programming RemoteIn-office Medtronic CareLink® Home MonitorProvidedNot Provided Clinical Management Alerts AT/AF BurdenAutomatic Clinician Alert, 12 hrs/dayOff Fast V. Rate during AT/AFAutomatic Clinician Alert, 120 bpm x 6 hrs AT/AF /dayOff Number of Shocks DeliveredAutomatic Clinician Alert, 2 Shocks DeliveredOff All Therapies Exhausted in a ZoneAutomatic Clinician AlertOff Lead / Device Integrity Alerts Lead Impedance Out of RangeAutomatic Clinician and Audible Patient AlertAudible Patient Alert VF Detection / Therapy OffAutomatic Clinician and Audible Patient AlertAudible Patient Alert Low Battery VoltageAutomatic Clinician and Audible Patient AlertAudible Patient Alert Excessive Charge TimeAutomatic Clinician and Audible Patient AlertAudible Patient Alert

All events that did or would have triggered alerts if device programmed accordingly included –Events that triggered alerts: the center logged date of clinical decision –Events that did not trigger alerts: date of decision was date of first device interrogation following event –Time to decision determined for each event, and for each subject with an event, these times were averaged –Due to skewness of data, nonparametric test used to compare time to decision per patient between arms For health care utilization, multiple events proportional hazards models used to compare rates of each of the following between arms: –Cardiovascular hospitalizations –ED visits –Unscheduled clinic visits, including urgent care visits Study Methods

Study Demographics Patient CharacteristicsRemote (n=1014)In-office (n=983) Male70.5%71.7% Age (years)65.2 ± ± 11.9 CRT-D36.4%35.3% LVEF (%)28.6 ± ± 10.3 NYHA No HF Class I Class II Class III Class IV 5.3% 3.9% 40.9% 48.5% 1.5% 6.7% 4.7% 39.5% 47.5% 1.5%

Primary Endpoint Event to Clinical Decision (median time) (per patient with at least one event) Time from event to clinical decision in the Remote Arm was significantly shorter than in the In-office Arm (p<0.001) Median time in the Remote arm was 4.6 days vs. 22 days in the In-office arm Note: Data includes events for patients who crossed over, were non- compliant or had alerts occur prior to home monitor setup

Time from Event to Decision by Alert Type (median days) Device EventNo. of Events (No. of Patients) No. of Days from Event Onset To Clinical Decision Median (Interquartile Range) RemoteIn-officeRemoteIn-office AT/AF burden at least 12 hrs 437 (107)280 (105)3 (1, 15)24 (7, 57) Fast V rate at least 120 bpm during at least 6 hrs AT/AF 41 (26)47 (37)4 (2, 13)23 (5, 40) At least 2 shocks delivered in an episode 44 (35)32 (23)0 (0, 1.5)0 (0, 2) Lead impedances out of range 26 (18)12 (6)0 (0, 9)17 (5.5, 45) All therapies in a zone exhausted for an episode 16 (12)11 (6)0 (0, 1)9 (0, 36) VF detection/therapy off 10 (10)8 (8)0 (0, 0)0 (0, 84) Low battery 1 (1) 300 Overall 575 (172)391 (145)3 (0, 13)20 (4, 52)

Results of Clinician Alert Transmissions (Remote Arm)

Clinician Alert Transmissions

Clinic Visits (Scheduled and Unscheduled) By replacing routine clinic visits with remote monitoring, the observed rate of total clinic visits per patient year was Remote (3.92) vs. In-office (6.27)

Health Care Utilization Visits by Treatment Arm * Includes Urgent Care Visits

Impact of Remote Management Remote Arm = 3.3 days per hospitalization In-office Arm = 4 days per hospitalization Mean reduction 18% Estimated savings per hospitalization $1,659* This study showed the Remote Arm had significantly shorter hospitalization length of stays than In-office Arm (p=0.002) (p = 0.002) * Estimated using the Medicare Limited Data Set - Standard Analytic Files from

Conclusions A significant reduction in time from onset of events to clinical decisions in response to arrhythmias, and device issues Replacement of routine in-clinic visits with remote transmissions did not significantly increase other health care utilizations (cardiovascular hospitalizations, emergency department, and unscheduled clinic visits) A significant reduction in mean length of stay per cardiovascular hospitalization In this study monitoring patients remotely with automatic clinician alerts showed: